COVID-19: combining antiviral and anti-inflammatory treatments
By J. Stebbing, A. Phelan, Ivan Griffin, C. Tucker, O. Oechsle, Daniel P. Smith, Peter J. Richardson. Lancet. Infectious Diseases (Print), 2020
962 citations recorded by the source corpus.
400 www.thelancet.com/infection Vol 20 April 2020 5 WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. 2014. http://apps.who.int/iris/rest/ bitstreams/604045/retrieve (accessed Feb 20, 2020). 6 Arabi Y, Balkhy H, Hajeer AH. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015; 4: 709. 7 Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447–56. 8 Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144: 464–73. 9 Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80–90. 10 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599–609. 15 Schoofs T, Klein F, Braunschweig M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 2016; 352: 997–1001. 12 Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016; 352: 1001–04. 13 WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. https://www.who. int/docs/default-source/coronaviruse/clinical-management-of-novel-cov. pdf (accessed Feb 20, 2020). 14 Clark DR, Jonathan EM, JKB. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; published online Feb 7. https://doi.org/10.1016/S0140-6736(20)30317-2.
Subfields: Computational Theory and Mathematics, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/ab865ecdd1e42f7f85ea36f57bf3aa31cb34f42d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment (2020, background): “Besides anti-viral agents, treatment of immunologic complications including cytokine storm using appropriate immunosuppressive and immunomodulatory drugs is essential [40, 41].”
- Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer (2023, background): “Baricitinib was also found to have a high affinity for numb-associated kinase (NAK) which enabled it to suppress NAK activity and block clathrin-mediated endocytosis to reduce viral infection in COVID-19.”
- COVID-19: immunopathogenesis and Immunotherapeutics (2020, methodology): “Moreover, baricitinib combined with direct-acting antivirals (lopinavir or ritonavir and remdesivir) were employed for patients with COVID-19 and showed reduced viral replication and aberrant host inflammatory response.(50,77) In T ab le 1.”
- Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy? (2020, background): “Recently published papers have found an imbalance in T cells, as well as high serum levels of IL-6, IL-1 and TNFa (Qin et al., 2020) , in the subjects requiring hospitalization and admitted to ICU: this suggests an intriguing role of the most recent immunosuppressive drugs in the treatment of Covid-”